Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03217578

Neonatal Spinal Muscular Atrophy (SMA) Screening

Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of SMN1 gene. If neonates have positive SMA screening test, further confirmation with multiplex ligation-dependent probe amplification (MLPA) test and prospective motor function monitoring including physical and neurological examinations will be proved to make SMA confirmation. For any confirmed SMA patient, genetic counseling and standard of care will be proved.

Recruiting

Interested in participating?

Request Info

Key information

Age range

0 week–2 week

Sex eligibility

All sexes

Study type

Observational

Primary location

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 807, Taiwan

Location status: Recruiting

Location contact

Yuh-Jyh Jong, MD

PRINCIPAL_INVESTIGATOR

Yun-Hui Chou

CONTACT

[email protected]

+886972977320

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Neonates born in Taiwan who receive regular newborn screening suggested by Ministry of Heath and Welfare.
  • Parents or legal guardian agree to perform SMA newborn screening.

Exclusion criteria

Parents or legal guardian do not agree to perform SMA newborn screening.

Treatment and study plan

SMA Newborn Screening

Other

Primary outcomes

  1. Number of neonates with confirmed the deletion of 2 copies of SMN1 gene

    Time frame: 3 years

    Neonates with positive SMA newborn screening will be confirmed by multiplex ligation-dependent probe amplification (MLPA) test

Secondary outcomes

  1. Number of neonates with confirmed SMA

    Time frame: 3 years

    Neonates with confirmed the deletion of 2 copies of SMN1 gene by MLPA test will be followed till SMA symptoms appear.

Study contacts

Contact information is provided by the study sponsor or research team.

Yun-Hui Chou

CONTACT

[email protected]

+886972977320

Sponsors and collaborators

Lead sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Other

Collaborators

  • Taipei Institute of Pathology
  • The Chinese Foundation of Health

Registry information

Official study title

Study on the Neonatal Screening of Spinal Muscular Atrophy

Acronym: SMA

Important dates

Study start
2017
Primary completion
2030
Study completion
2030
First posted
Jul 14, 2017
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.